

# Key Information Document

## Purpose

This information sheet provides you with key information about this investment product. It is not marketing material. This information is required by law to help you understand the type of product, the risks and costs involved as well as the potential profits and losses, and to help you compare it with other products.

---

## Product

**Product name** UBS (Lux) Investment SICAV 2 - UBS (Lux) Digital Health Equity Fund, class (EUR hedged) P-acc

**Manufacturer** UBS Asset Management (Europe) S.A.

ISIN LU1683285321

Telephone number Call +352 27 1511 for more information.

Website [www.ubs.com/funds](http://www.ubs.com/funds)

The Commission de Surveillance du Secteur Financier (CSSF) is responsible for supervising UBS Asset Management (Europe) S.A. in relation to this Key Information Document.

This PRIIP is authorized in Luxembourg.

UBS Asset Management (Europe) S.A. is authorised in Luxembourg and regulated by the Commission de Surveillance du Secteur Financier (CSSF).

Date of production of the KID: 14 April 2026.

---

## What is this product?

### Type

UBS (Lux) Investment SICAV 2 is an undertaking for collective investment in transferable securities (UCITS) incorporated in the legal form of an investment company with variable capital (SICAV) under Part I of the Luxembourg 2010 Law on undertakings for collective investment.

### Term

The Product does not have a maturity date (the Product has been established for an indefinite period of time). The Manufacturer may terminate the Product early. The amount you will receive upon early termination may be less than the amount you invested.

The recommended holding period (RHP) is displayed in the section "How long should I hold it and can I take money out early?".

### Objectives

Health care cost to society has risen to levels which are no longer sustainable. This fund invests globally in innovative companies which are driving a revolution in the health care sector through the application of technology. The investment universe comprises three segments: Research & Development, Treatments and Efficiency. The fund invests in "pure-play" digital health companies, which are typically small to mid-sized. The portfolio manager is not tied to the benchmark in terms of investment selection or weight.

The return of the fund depends primarily on equity market development and their exchange rate fluctuations, as well as dividend payments. Income of this share class is reinvested. The exchange rate risk of the share class currency is to a large extent hedged against the currency of the fund.

### Intended retail investor

This fund applies to retail investors with a basic financial understanding, who can accept a possible loss on the investment amount. The fund is aimed at growing the investment value, while granting daily access to the capital under normal market conditions. With their investment in this fund, investors can satisfy long term investment needs. The fund is suited to be acquired by the target client segments without any restriction of the distribution channel or platform.

### Depositary

UBS Europe SE, Luxembourg Branch

### Further Information

Information about UBS (Lux) Digital Health Equity Fund and the available share classes, the full prospectus, and the latest annual and semi-annual reports, as well as additional information can be obtained free of charge from the fund management company, the central administrator, the custodian bank, the fund distributors or online at [www.ubs.com/funds](http://www.ubs.com/funds). Latest price can be found at [www.ubs.com/funds](http://www.ubs.com/funds)

## What are the risks and what could I get in return?

Indicator



Lower risk

Higher risk



The risk indicator assumes you keep the product for 7 year(s).

The summary risk indicator is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because of movements in the markets or because we are not able to pay you.

We have classified this product as 5 out of 7, which is a medium-high risk class.

This rates the potential losses from future performance at a medium-high level. The past may be a poor predictor of the future and, hence, the actual risk of losing money may vary significantly.

**Be aware of currency risk. You will receive payments in a different currency, so the final return you will get depend on the exchange rate between the two currencies. This risk is not considered in the indicator shown above.**

The product may be exposed to further risk factors such as operational, political and legal risks which are not included in the summary indicator. Please refer to the prospectus for more detail.

This product does not include any protection from future market performance so you could lose some or all of your investment.

If we are not able to pay you what is owed, you could lose your entire investment.

### Performance Scenarios

What you will get from this product depends on future market performance. Market developments in the future are uncertain and cannot be accurately predicted.

The unfavourable, moderate and favourable scenarios shown are illustrations using the worst, average, and best performances of the product over the last 12 years. Markets could develop very differently in the future.

Recommended holding period:		7 Years	
Example Investment:		EUR 10 000	
		If you exit after 1 year	If you exit after 7 years
<b>Scenarios</b>			
<b>Minimum</b>	<b>There is no minimum guaranteed return. You could lose some or all of your investment.</b>		
<b>Stress</b>	<b>What you might get back after costs</b>	EUR 1 840	EUR 440
	Average return each year	-81.6%	-36.0%
<b>Unfavourable</b>	<b>What you might get back after costs</b>	EUR 4 630	EUR 3 190
	Average return each year	-53.7%	-15.1%
<b>Moderate</b>	<b>What you might get back after costs</b>	EUR 9 980	EUR 14 230
	Average return each year	-0.2%	5.2%
<b>Favourable</b>	<b>What you might get back after costs</b>	EUR 18 450	EUR 33 610
	Average return each year	84.5%	18.9%

The stress scenario shows what you might get back in extreme market circumstances.

The figures shown include all costs of the product itself. The figures do not take account of your personal tax situation, which can also have an impact on how much you receive back.

Unfavourable scenario: This type of scenario occurred for an investment between 2021 and 2025.

Moderate scenario: This type of scenario occurred for an investment between 2016 and 2023.

Favourable scenario: This type of scenario occurred for an investment between 2014 and 2021.

### What happens if UBS Asset Management (Europe) S.A. is unable to pay out?

Losses are not covered by any investor compensation or guarantee scheme. In addition, UBS Europe SE, Luxembourg Branch, the depositary of the Fund responsible for safekeeping its assets (the "Depositary"), is subject to a potential default risk in the event that the assets of the Fund held with the Depositary are lost. However, this risk of default is limited as the Custodian is required by law and regulation to segregate its own assets from the Fund's assets. The Custodian shall be liable to the Fund or the Fund's investors for any loss of a financial instrument held in custody by the Custodian or its delegate, unless the Custodian can demonstrate that the loss resulted from an external event beyond its control.

## What are the costs?

The person advising on or selling you this product may charge you other costs. If so, this person will provide you with information about these costs and how they affect your investment.

### Costs over time

The table shows the amounts that are taken from your investment to cover different types of costs. These amounts depend on how much you invest, how long you hold the product and how well the product does. The amounts shown here are illustrations based on an example investment amount and different possible investment periods.

We have assumed:

- In the first year you would get back the amount that you invested (0% annual return). For the other holding periods, we have assumed that the product performs as shown in the moderate scenario.
- 10 000 EUR is invested.

	If you exit after 1 year	If you exit after 7 years
Total costs	EUR 708	EUR 2 143
Annual cost impact (*)	7.1%	2.8% each year

(\*) This illustrates how costs reduce your return each year over the holding period. For example, it shows that if you exit at the recommended holding period your average return per year is projected to be 8.0% before costs and 5.2% after costs.

We may share part of the costs with the person selling you the product to cover the services they provide to you. They will inform you of the amount.

### Composition of costs

One-off costs upon entry or exit		If you exit after 1 year
Entry costs	5.0% of the amount you pay in when entering this investment. This is the most you will be charged. The person selling you the product will inform you of the actual charge.	Up to EUR 500
Exit costs	We do not charge an exit fee for this product, but the person selling you the product may do so.	EUR 0
Ongoing costs taken each year		
Management fees and other administrative or operating costs	1.9% of the value of your investment per year. This is an estimate based on actual costs over the last year.	EUR 191
Transaction costs	0.2% of the value of your investment per year. This is an estimate of the costs incurred when we buy and sell the underlying investments for the product. The actual amount will vary depending on how much we buy and sell.	EUR 17
Incidental costs taken under specific conditions		
Performance fees	There is no performance fee for this product.	EUR 0

The figures shown here do not include any additional charges that may be levied by your distributor, adviser or any "insurance wrapper" into which the fund may be placed. Additional information on costs can be found in the sales prospectus at [www.ubs.com/funds](http://www.ubs.com/funds)

## How long should I hold it and can I take money out early?

### Recommended holding period: 7 Year(s)

The recommended holding period for this product is 7 year(s). This is our recommended holding period based on the risk and expected return with the product. Please note that the expected return is not guaranteed. The more the actual holding period deviates from the recommended holding period for the product, the more your actual return will also deviate from the product assumptions. Depending on your needs and limitations, a different holding period may be suitable for you. Consequently, we recommend that you discuss this issue with your customer service representative.

In principle, investors may ask the Management Company to redeem their units on any business day in Luxembourg.

### How can I complain?

If you have a complaint about the product, the producer of the product or the person who recommended or sold you the product, please

contact your customer service representative or contact us at [www.ubs.com/ame-regulatorydisclosures](http://www.ubs.com/ame-regulatorydisclosures)

UBS Asset Management (Europe) S.A., The Complaint handling Director, 33A, Avenue J.F. Kennedy, B.P.91, L-2010 Luxembourg, Email: [OL-UBSAME-complainthandling@ubs.com](mailto:OL-UBSAME-complainthandling@ubs.com)

### Other relevant information

Information on past performance and previous performance scenario calculations can be found at [www.ubs.com/funds](http://www.ubs.com/funds)